OpGen is involved in molecular microbiology focused on combating antimicrobial resistance (AMR).

OpGen

OpGen, Inc. | 3,633 followers on LinkedIn. Mission

We harness the power of molecular microbiology to develop diagnostic solutions that will optimize the treatment of life-threatening, drug resistant infections. We seek to dramatically transform patient care to guide antibiotic therapy selection and help improve antibiotic stewardship.

About

Headquartered in Rockville, Maryland, OpGen (NASDAQ:OPGN) is a precision medicine company harnessing the power of molecular diagnostics to help combat infectious disease.

Chief Marketing and Scientific Affairs Officer, OpGen, Inc.

Faranak Atrzadeh

Human Resources Generalist at OpGen, Inc.

Harlene Stanchfield, PHR

CFO at Immunomic Therapeutics, Inc.

Eric Winzer

Corporate Controller at OpGen, Inc.

David Caplon, CPA

OpGen, Inc.

HSTS

IPv6

jQuery CDN

Common Name Invalid

Invalid Certificate Dates

SiteGround CAPTCHA

Mobile Optimized

Akamai Hosted

Drupal

Level 3 Communications

Noel Doheny

President and CEO

Oliver Schacht

Chief Financial Officer

Tim Dec

Chief Information Officer

Vadim Sapiro

SVP US Sales

Derek Joesting

Director, Corporate Affairs and Human Resources

Christine Cornell

Director, Product Management

Daria Snack

Finance and Administration

Don Elsey

Independent Director

Yvonne Schlaeppi

Corporate Controller

Prabhavathi Fernandes

Mario Crovetto

R Don Elsey

William Rhodes

Johannes Bacher

Chief Operating Officer

Albert Weber

Chief Marketing and Scientific Affairs Officer

Albert Risdorfer

Sr Director Human Resources

Biotechnology Companies With Less Than $10M in Revenue (Top 10K)

Maryland Companies (Top 10K)

Health Care Companies With Less Than $10M in Revenue (Top 10K)

United States Genetics Companies

OpGen is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious diseases. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with more rapid and actionable information about life-threatening infections to improve patient outcomes.  

The company's approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR).  By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs).
 
OpGen was established in 2002 by David Schwartz in Rockville, Maryland.

David E Lazar

Post-IPO Equity - OpGen

Merck Global Health Innovation Fund

Sabby Management

Rockville

Maryland

United States

North America

OpGen Shares Suspended From Trading on Nasdaq

OpGen Submits Plan to Nasdaq After Missing Another Listing Requirement

OpGen Out of Compliance With Additional Nasdaq Listing Requirement

OpGen trading halted, news pending

OpGen announces 1-for-10 reverse stock split

OpGen Provides Update on Business Operations and Strategic Opportunities

OpGen receives noncompliance notice from Nasdaq

Why Is Penny Stock OpGen Trading Higher On Tuesday?

OpGen Announces Acquisition of Preferred Stock by David Lazar

Austria

Europe

Malaysia

Asia

India

Pakistan

HTML5

Google Fonts

Bootstrap

Cloudflare CDN

Google Compute Engine

Vimeo

Google Analytics

Wordpress

jQuery

Microsoft Outlook

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

news impact assignment basic	general
public peers	general	Nov 19, 2024 6:25 AM	bd4596f9
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 6:25 AM	eed34c23
crunchbase trigger	general	Nov 19, 2024 6:25 AM	22901413
crunchbase profile	general	Nov 20, 2024 12:28 AM	5378390b
li profile	general	Nov 19, 2024 6:25 AM	da0dd24f
translate crunchbase fundingrounds	general	Nov 20, 2024 1:22 AM	e28ac87a
peers	general	Nov 19, 2024 6:25 AM	b3e17981
news basic	general	Nov 19, 2024 6:25 AM	80097ff1
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:OPGEN

OpGen

Last Close

1.81

22/11 19:36

Market Cap

4.02M

Beta: -

Volume Today

850

Avg: -